Entrada Therapeutics (TRDA) Other financing activities (2020 - 2026)

Entrada Therapeutics' Other financing activities history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 71.43% year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was $212000.0, a 70.47% decrease from a year earlier, with the FY2025 full-year figure at $462000.0, down 19.51% from the prior year.
• Other financing activities climbed to $100000.0 in Q1 2026 per TRDA's latest filing, from $84000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $1.1 million in Q2 2024 and bottomed at -$1.0 million in Q3 2024.
• The 5-year median for Other financing activities is $100000.0 (2026), against an average of $104352.9.
• Biggest YoY gain for Other financing activities was 614.0% in 2023; the steepest drop was 520.27% in 2023.
• Year by year, Other financing activities stood at $74000.0 in 2022, then slumped by 520.27% to -$311000.0 in 2023, then soared by 200.0% to $311000.0 in 2024, then slumped by 72.99% to $84000.0 in 2025, then climbed by 19.05% to $100000.0 in 2026.
• Per Business Quant, the three latest TRDA Other financing activities figures stand at $100000.0 (Q1 2026), $84000.0 (Q4 2025), and $8000.0 (Q3 2025).